Abstract
Background
Surgical site infections (SSIs) constitute a major clinical problem in terms of morbidity, mortality, duration of hospital stay, and overall costs. The bacterial pathogens implicated most frequently are Streptococcus pyogenes (S. pyogenes) and Staphylococcus aureus (S. aureus). The incidence of methicillin-resistant S. aureus (MRSA) SSIs is increasing significantly. Since these infections have a significant impact on hospital budgets and patients’ health, their diagnosis must be anticipated and therapy improved. The first step should be to evaluate risk factors for MRSA SSIs.
Methods
Through a literature review, we identified possible major and minor risk factors for, and protective factors against MRSA SSIs. We then submitted statements on these factors to 228 Italian surgeons to determine, using the Delphi method, the degree of consensus regarding their importance. The consensus was rated as positive if >80% of the voters agreed with a statement and as negative if >80% of the voters disagreed. In other cases, no consensus was reached.
Results
There was positive consensus that sepsis, >2 weeks of hospitalization, age >75 years, colonization by MRSA, and diabetes were major risk factors for MRSA SSIs. Other possible major risk factors, on which a consensus was not reached, e.g., prior antibiotic use, were considered minor risk factors. Other minor risk factors were identified. An adequate antibiotic prophylaxis, laparoscopic technique, and infection committee surveillance were considered protective factors against MRSA SSIs. All these factors might be used to build predictive criteria for identifying SSI due to MRSA.
Conclusions
In order to help to recognize and thus promptly initiate an adequate antibiotic therapy for MRSA SSIs, we designed a gradation of risk and protective factors. Validation, ideally prospective, of this score is now required. In the case of a SSI, if the risk that the infection is caused by MRSA is high, empiric antibiotic therapy should be started after debriding the wound and collecting material for culture.
Keywords: Acute bacterial skin and skin structure infections, Surgical site infection, MRSA, Dalbavancin
Background
Surgical site infections: background
The Food and Drug Administration (FDA) recently proposed a new classification of skin and soft tissue infections namely acute bacterial skin and skin structure infections (ABSSSIs) which comprise erysipelas, cellulitis, major subcutaneous abscesses, and wound infections, including surgical site infections (SSIs). An ABSSSI is a bacterial infection of the skin with a lesion area of at least 75 cm2, measured by redness, edema, or induration [1]. ABSSSIs constitute a significant burden for the healthcare system and their incidence is increasing. They have become a challenging clinical problem associated with high direct and indirect costs. Bacterial pathogens that commonly cause ABSSSIs include S. pyogenes and S. aureus, including a large number of methicillin-resistant S. aureus (MRSA) strains.
Given the associated morbidity, mortality, length of hospital stay, and overall direct and indirect costs, SSIs represent a significant problem [2–4]. Moreover, MRSA infections can have an even greater impact on hospital budgets and on patients’ health, since they are more severe, may lead to longer hospital stays, and are associated with higher mortality.
Despite progresses in prevention, SSIs remain one of the most common adverse events in hospitals, accounting for 11 to 26% of all healthcare-associated infections [5]. In Italy, the rate of SSIs ranged from 5.4 to 12.8%, although recent studies have shown a reduction to 5%, [6, 7]. Surgical patients can develop several types of post-operative infection, with wound infections being the most common. The specific surgical procedures for each specialty are associated to different percentages of SSIs [8]. These complications add 10–20% additional extra costs to the total hospital bill [9].
In the USA, for any given type of operation, the development of a wound infection will approximately double the cost of hospitalization. These infections lead to 80,000 deaths per year and are associated with an annual treatment cost of US$2 billion [10]. A similar scenario has been found in Italy, where nosocomial infections occur in 500,000 out of 8,000,000 hospital admissions per year [11].
SSIs caused by S. aureus may be life threatening (estimated mortality rate 5%) and account for more than two extra weeks of hospitalization and around US$50,000 extra cost [12]. Rates of MRSA infection are increasing dramatically, and there is an urgent need to reduce hospitalizations and costs and implement more effective outpatient management and treatment strategies. Since cost containment and cost-efficient patient management are top priorities today, for the whole healthcare system, many hospitalized patients with SSIs could be safely treated, as outpatients, with current options of intravenous antibiotic therapy. This would reduce costs for hospitalization and could also improve patients’ outcome and satisfaction.
Diagnosis-related groups and the incidence of surgical site infections
The exact incidence of SSIs is difficult to determine. In fact, the Diagnosis-Related Group (DRG) system underestimates the rate of SSIs, due to a very early discharge of surgical patients. Hospitals without a surveillance system report infection rates of less than 5%. This figure probably underestimates the problem, mostly because many SSIs are diagnosed after the patient has been discharged from hospital [8]. For example, Petrosillo et al. described that SSIs occurred in 5.2% out of 4665 patients and that, while 148 SSIs (61.4%) were diagnosed during the patients’ stay in hospital, 93 (38.6%) were recorded within 30 days after discharge [13]. This is comparable to the 34.8% result found in another Italian study on general surgery patients reported by Fiorio et al. [14]. However, in another similar surveillance study, higher post-discharge rates of SSI were found [15]. Marchi et al. reported data on non-prosthetic surgery from the Italian SSI surveillance program for the period 2009 to 2011, based on 60,460 operations from 355 surgical wards: SSIs were observed in 1628 cases (2.6%), with 60% of these being diagnosed on day 30 post-discharge surveillance [16].
Thus, up to 60% of SSIs are diagnosed after discharge from hospital, and this trend is increasing as the length of post-operative hospital stay is getting shorter and the number of 1-day surgery procedures is increasing [17].
According to current literature, active infection surveillance is useful in reducing the incidence of SSIs through surveillance-induced infection control efforts [18]. Operations performed in hospitals with at least 2 years of surveillance showed a 29% lower risk of SSIs, confirming that surveillance is a protective factor in preventing SSIs [16].
Classification of surgical site infections
The identification of SSIs involves interpretation of clinical and laboratory findings. The Centers for Disease Control and Prevention (CDC) National Nosocomial Infections Surveillance (NNIS) system has developed standardized surveillance criteria for defining SSIs [19]. Using these criteria, SSIs are classified as either incisional or organ/space. Incisional SSIs are further divided into those involving only skin and subcutaneous tissue (superficial incisional SSIs) and those involving deeper soft tissues of the incision (deep incisional SSIs). Organ/space infections are not included in ABSSSIs.
Predominant pathogens in surgical site infections
According to the NNIS system reports, the most commonly encountered pathogens in SSIs are Gram-positive cocci, particularly Staphylococcus aureus (S. aureus), coagulase-negative staphylococci (CoNS), Streptococcus pyogenes (S. pyogenes), and Enterococcus spp., followed by Escherichia coli, Pseudomonas aeruginosa and Enterobacter spp. [20]. The source of pathogens is often the endogenous flora of the patient’s skin, mucous membranes, or hollow viscera [21]. Microorganisms of endogenous flora are usually aerobic Gram-positive cocci (e.g., staphylococci), but may also include fecal flora (e.g., anaerobic bacteria and Gram-negative aerobes) [22].
Exogenous sources of pathogens involved in SSIs include surgical personnel (especially members of the surgical team), the operating room environment (including air), and all tools, instruments, and materials brought to the sterile field. Exogenous flora consists primarily of aerobes, especially Gram-positive organisms (e.g., staphylococci and streptococci) [23].
Besides S. aureus and CoNS, Staphylococcus epidermidis may be responsible for severe infections following implantation of any prosthesis in general surgery, cardiac surgery, orthopedics, etc. Such infections may require removal of the prosthesis.
Table 1 lists the more frequent pathogens, according to surgical procedure.
Table 1.
Most frequently encountered pathogens, according to the surgical procedure [8]
| Type of surgery | Likely pathogens |
|---|---|
| Placement of grafts, prostheses, or implants | S. aureus, coagulase-negative staphylococci |
| Cardiac | S. aureus, coagulase-negative staphylococci |
| Neurosurgery | S. aureus, coagulase-negative staphylococci |
| Breast | S. aureus, coagulase-negative staphylococci |
| Ophthalmic (limited data; anterior segment resection, vitrectomy, and scleral buckling) | S. aureus, coagulase-negative staphylococci, streptococci, Gram-negative bacilli |
| Orthopedic (total joint replacement, closed fractures/use of nails, plates, other internal fixation device, functional repair without implant/device trauma) | S. aureus, coagulase-negative staphylococci, Gram-negative bacilli |
| Non-cardiac thoracic (lobectomy, pneumonectomy, wedge resection, other non-cardiac mediastinal procedures), closed tube thoracotomy | S. aureus, coagulase-negative staphylococci, S. pneumoniae, Gram-negative bacilli |
| Vascular | S. aureus, coagulase-negative staphylococci |
| Appendectomy | Gram-negative bacilli, anaerobes |
| Biliary tract | Gram-negative bacilli, anaerobes |
| Colorectal | Gram-negative bacilli, anaerobes |
| Gastroduodenal | Gram-negative bacilli, streptococci, oropharyngeal anaerobes (e.g., peptostreptococci) |
| Head and neck (mainly procedures with incision through oropharyngeal mucosa) | S. aureus, streptococci, oropharyngeal anaerobes (e.g., peptostreptococci) |
| Obstetric and gynecological | Gram-negative bacilli, enterococci, group B streptococci, anaerobes |
| Urological | Gram-negative bacilli |
S. aureus Staphylococcus aureus
Staphylococcus aureus in surgical site infections
S. aureus is consistently the leading cause of nosocomial infections, including SSIs. The incidence of MRSA strains is rising dramatically, and the amount of hospitalizations has more than doubled, in the past decade. Remarkably, MRSA is the main pathogen causing SSIs in many academic and community hospitals [24]. This represents a significant, independent risk factor for adverse clinical and economic outcomes. Kirkland et al. estimated that the excess hospital costs associated with MRSA SSIs ranged from US$3089 to US$35,367 [3]. Engemann et al. found that, among surgical patients, those with MRSA infections were hospitalized 5 days longer than those with methicillin-sensitive S. aureus (MSSA) infections [25]. Hospital charges for MRSA patients were also US$62,908 greater than for patients without an infection and US$40,000 greater than for patients with MSSA infections.
Other studies support the findings that patients with MRSA infections require more health-care resources than patients with MSSA infections [26]. Weigelt et al. determined that the risk-adjusted attributable increase in duration of hospitalization was approximately 1 day and, in terms of costs for the hospitalization, over US$1000. They also found that significant independent risk factors, increasing costs, and time spent in hospital for SSIs due to MRSA, included illness severity, transfer from another healthcare facility, a previous hospital admission (30 days), and other polymicrobial infections (p < 0.05) [27].
Methicillin-resistant Staphylococcus aureus
MRSA is a versatile and dangerous bacterial pathogen that shows virulence, antibiotic resistance, and survival fitness [28]. Selection pressure, exercised by broad-spectrum antibiotic treatment and cross-transmission through healthcare workers’ hands, facilitates its spreading. Hence, profiles to identify patients at high risk of MRSA carriage might improve prevention of MRSA infections because MRSA carriers, without symptomatic infection, are an important pathogen reservoir [29].
Efforts should be made to identify patients at risk of colonization and subsequent infection by multi-drug-resistant microorganisms such as MRSA, and to control hospital-acquired SSIs. Remarkably, surveillance systems, even without any specific intervention, have been associated with a reduction in SSIs [30]. Because all authors do not recommend a universal rapid MRSA screening, other methods to pick out patients at high risk of MRSA colonization and subsequent SSIs could be very useful.
Harbart et al. found that age 75 years or older, previous hospitalization (in the preceding 12 months), and recent antibiotic therapy (in the preceding 6 months) were the strongest risk factors for MRSA colonization in surgical patients, then confirmed in a validation cohort [31].
Applying the Delphi method, we recently identified the most common risk factors for colonization and/or infection by MRSA as being patient from a long-term care facility, previous hospitalization (within the preceding 30 days), Charlson score >5, chronic obstructive pulmonary disease and thoracic surgery, antibiotic therapy with beta-lactams (especially cephalosporin and carbapenems) and/or quinolones in the preceding 30 days, age 75 years or older, current duration of hospital admission >16 days, and prosthetic implant surgery. Furthermore, protective factors were an adequate antibiotic prophylaxis, laparoscopic surgery, and the presence in the hospital of an active surveillance program for infection control [8].
Therapy for methicillin-resistant Staphylococcus aureus
Clinical MRSA isolates show a decreased susceptibility or increased resistance to anti-MRSA drugs. Thus, treatment of ABSSSIs is now challenged by toxicity, few oral options, and greater need for hospitalization and its associated costs [32].
The Infectious Diseases Society of America (IDSA) recommended beta-lactam or clindamycin for mild/moderate non-purulent ABSSSIs, and vancomycin plus piperacillin/tazobactam for severe non-purulent ABSSSIs treatments [33]. In purulent ABSSSIs, doxycycline or trimethoprim/sulfamethoxazole should cover MRSA for moderate cases and vancomycin, daptomycin, linezolid, or ceftaroline in severe cases. Antimicrobials available in Italy for treating ABSSSIs with activity against MRSA and other resistant Gram-positive pathogens include vancomycin, teicoplanin, daptomycin, linezolid, and ceftaroline. Of these antimicrobials, only linezolid is available in an oral formulation.
Table 2 reports the main characteristics of anti-MRSA drugs for SSIs. Some of these drugs have significant potential toxicity (e.g., myopathy from daptomycin, renal function impairment from vancomycin, bone marrow suppression from linezolid) and drug interactions (e.g., linezolid and selective serotonin re-uptake inhibitors). While doxycycline and trimethoprim/sulfamethoxazole are active against MRSA, their activity against beta-hemolytic streptococci is poor, limiting their use as monotherapy for ABSSSIs.
Table 2.
Main characteristics of the antibiotics used for the treatment of SSIs due to MRSA [8]
| Antibiotic | Bactericidal activity; pharmacodynamics; anti-biofilm activity | Route of administration | Doses | Adverse events | Interactions | Cost (for a 70 kg person) |
|---|---|---|---|---|---|---|
| Teicoplanin | Bactericidal with low MIC; time-dependent; None | iv, im | 7-10 mg/Kg once daily, loading dose | Renal toxicity | None | €50-70/day |
| Vancomycin | Bactericidal with low MIC; time-dependent; None | iv | 1 g twice daily, 500 mg four times a day | Renal toxicity | Other nephrotoxic drugs | €5/day |
| Daptomycin | Bactericidal; concentration-dependent; Yes | iv | 4-6 mg/kg | Myotoxicity | Statins | €80-120/day |
| Linezolid | Bacteriostatic; time-dependent; None | iv, oral | 1200 mg once daily | Bone marrow toxicity, neuropathy, serotoninergic syndrome | SSRIs | €120/day |
| Tigecycline | Bacteriostatic; time-dependent; Partial | iv | 50 mg twice daily; 100 mg loading dose | Nausea, vomiting, pancreatitis | None | €120/day |
| Ceftaroline | Bactericidal; time-dependent; None | iv | 600 mg twice daily | Rash | None | €96/day |
| Dalbavancin | Bactericidal; concentration-dependent; Yes | iv | 1000 mg day 1, 500 mg after 7 days; or 1500 mg one-shot | No | None | NA |
| Cotrimoxazole | Bactericidal; time-dependent; None | iv, oral | 800/160 mg 3 times a day | Anemia | None | €15/day |
| Rifampin | Bactericidal; time-dependent; Yes | iv, oral | 600 mg once a day | Liver toxicity | Several | €6/day |
iv intravenous, im intramuscular, SSRIs selective serotonin re-uptake inhibitors
Dalbavancin, a novel lipoglycopeptide antibiotic active against both MSSA and MRSA, was approved by the FDA in May 2014 and by the European Medicines Agency (EMA) in February 2015 for the treatment of ABSSSIs caused by susceptible Gram-positive organisms [34]. Several clinical trials have demonstrated its tolerability, efficacy, and non-inferiority compared to standard therapy for ABSSSIs. The DISCOVER 1 and DISCOVER 2 studies showed that once-weekly intravenous dalbavancin was not inferior to twice-daily intravenous vancomycin, followed by oral linezolid for the treatment of ABSSSIs. Adverse events were reported less frequently in patients treated with dalbavancin, than in those treated with vancomycin-linezolid [35]. Dalbavancin’s high-protein binding and prolonged half-life allow for easily and consistently attainable therapeutic levels. It has a well-established activity against the Gram-positive organisms commonly involved in superficial and deep SSIs, including MRSA and other multidrug-resistant pathogens, and the MIC90 values for these organisms have remained stable over the past decade.
Dalbavancin, as an anti-MRSA agent, displays advantageous factors, such as bactericidal effect, full activity on biofilm [36], which could be increased by combination with rifampicin, lack of drug-drug interactions, lack of renal toxicity, and no adverse events associated with an early discharge from hospital, because of its prolonged half-life. Indeed, the most unique feature of dalbavancin is its once-weekly dosing, previously approved as a 1000 mg dose followed by 500 mg 1 week later, and then the one-shot, single-dose of 1500 mg, recently approved by the EMA [37].
The aim of this study was to create a score for the early recognition of SSIs caused by MRSA in order to facilitate the prompt initiation of adequate antibiotic therapy.
Methods
After a systematic literature review on SSIs (randomized clinical trials, case-control studies, recommendations and case reports), we proposed some major and minor risk factors, and protective factors, drawn from the literature and identified in a previous work [8], to an expert board of general and specialist surgeons.
Delphi methodology
The Delphi method is a widely used technique to define standards, therapies, and care procedures based on the opinions of groups of experts [38–40].
An algorithm method may be useful for identifying patients without risk factors (high negative predictive model) but may be less efficient at identifying the true positives (low positive predictive value). With the Delphi method, each participant expresses his or her opinion anonymously, contributing to create the expert opinion of the entire group. The participants are asked to respond to a questionnaire, divided into statements, and independently assign a score ranging from 1 (which corresponds to “maximum disagreement”) up to 5 (which corresponds to “absolute agreement”).
We considered a positive consensus when more than 80% of the participants agree with the statement proposed and negative consensus when >80% of the participants disagree with it. In other cases, a consensus was not reached.
Here, 228 surgeons, members of the Italian Society of Surgeons, were asked to find a possible consensus on risk factors for MRSA, using the Delphi method [38–40]. The questions, based on a review of the literature and our previous research, concerned major and minor risk factors for and protective factors against SSIs due to MRSA.
Results
Having identified possible major and minor risk factors for MRSA SSIs, as well as potential protective factors, we determined the level of consensus regarding these factors among a large group of Italian surgeons using the Delphi method. Consensus was achieved when more than 80% of the group agreed (positive consensus) or disagreed (negative consensus) on a statement proposed.
Table 3 reports the submitted risk and protective factors with the rate of agreement. The questions were rated as major and minor risk factors for SSIs due to MRSA.
Table 3.
Risk factors for and protective factors against MRSA SSIs with the level of agreement obtained by the Delphi method
| Risk factors for SSIs due to MRSA | Percentage of consensus |
|---|---|
| Major risk factors for MRSA SSIs | |
| Signs and severity of sepsis | Consensus (>80%) |
| Colonization by MRSA | Consensus (>80%) |
| Age > 75 years | Consensus (>80%) |
| Duration of hospitalization > 2 weeks | Consensus (>80%) |
| Previous treatment with antibiotics, from 30 days to 12 months | No consensus (<80%) |
| ICU admission in the previous 12 months | No consensus (<80%) |
| Any prosthetic surgery | No consensus (<80%) |
| Previous admission to hospital (6 months) and/or rehabilitation structure | No consensus (<80%) |
| Minor risk factors for MRSA SSIs | |
| Diabetes (HbA1c > 7%) | Consensus (>80%) |
| Obesity (BMI > 30) | No consensus (<80%) |
| Steroids and immunosuppressive treatment | No consensus (<80%) |
| Previous hospital admission from 30 days to 6 months | No consensus (<80%) |
| Renal insufficiency | No consensus (<80%) |
| Chronic obstructive pulmonary disease | No consensus (<80%) |
| Other antibiotic therapy from 30 days to 6 months | No consensus (<80%) |
| Surgical operation lasting more than 3 h | No consensus (<80%) |
| Protective factors for MRSA SSIs | |
| Adequate antibiotic prophylaxis | Consensus (>80%) |
| Laparoscopic technique | Consensus (>80%) |
| Hospital with an Infection Surveillance Committee | Consensus (>80%) |
ICU intensive care unit, HbA1c, glycated hemoglobin, BMI body mass index
A positive consensus was reached on the fact that sepsis, >2 weeks spent in hospital, age >75 years, and colonization by MRSA were major risk factors for MRSA SSIs (Table 4). The board also agreed that diabetes was a minor risk factor for MRSA SSIs. Other possible risk factors, on which a consensus was not reached, i.e., antibiotic use in the preceding year, ICU admission in the preceding year, prosthetic surgery, admission to hospital or rehabilitation facility within the preceding 6 months, obesity, steroids and immunosuppressive treatment, renal insufficiency, chronic obstructive pulmonary disease, and surgery lasting more than 3 h, were considered minor risk factors. An adequate antibiotic prophylaxis, laparoscopic technique, and infection committee surveillance were considered strong factors protecting against MRSA SSIs (Table 4).
Table 4.
Suggested score to assess the risk of MRSA SSIs
| MRSA SSIs risk and protective factors | |
|---|---|
| Sepsis signs and severity | Major risk factor |
| Duration of hospitalization > 2 weeks | Major risk factor |
| Age > 75 years | Major risk factor |
| Colonization by MRSA | Major risk factor |
| Diabetes (HbA1c > 7) | Major risk factor |
| Procalcitonin dosage >3 mg/dl | Minor risk factor |
| Previous admission in hospital (6 months) and/or rehabilitation structure | Minor risk factor |
| Previous treatment with antibiotics, from 30 days to 12 months | Minor risk factor |
| ICU admission during the previous 12 months | Minor risk factor |
| Any prosthetic surgery | Minor risk factor |
| Obesity (BMI > 30) | Minor risk factor |
| Steroids and immunosuppressive treatment | Minor risk factor |
| Previous hospital admission from 30 days to 6 months | Minor risk factor |
| Renal insufficiency | Minor risk factor |
| Chronic obstructive pulmonary disease | Minor risk factor |
| Other antibiotic therapy from 30 days to 6 months | Minor risk factor |
| Surgical procedure lasting more than 3 h | Minor risk factor |
| Adequate antibiotic prophylaxis | Major protective factor |
| Laparoscopic technique | Major protective factor |
| Hospital with an Infection Surveillance Committee | Major protective factor |
ICU intensive care unit, HbA1c glycated hemoglobin, BMI body mass index
These factors should be validated in prospective studies, for better identification of patients at higher risk of developing MRSA SSIs or earlier identification of patients who already have an SSI, due to MRSA. To promptly start an appropriate, effective antibiotic therapy promptly, we proposed to identify major and minor risk and protective factors, to assess the risk of MRSA SSIs, as shown in Table 4, we merged results from a review of the literature and the Delphi consensus results described here. We think that these factors should be evaluated for predicting the need to start antibiotic therapy, given the high risk of the patient having a MRSA SSI.
Discussion
ABSSSIs have become a challenging clinical issue, associated with high direct and indirect costs. SSIs are an important subgroup of ABSSSIs and are associated with high rates of morbidity. Among other pathogens, MRSA is prevalent in ABSSSIs and in SSIs. Indeed, the rates of MRSA infection and related hospitalizations are increasing dramatically and MRSA has emerged as the most common cause of purulent infections. Besides, MRSA infection is a risk factor for subsequent hospitalization and death. In the management of surgical patients, it could therefore be very important to recognize if there are risk factors for the development of SSI caused by MRSA.
Through a systematic review of the literature and the consensus of 228 Italian surgeons, obtained by the Delphi method, we made an effort to identify and quantify the importance of risk factors for and protective factors against MRSA SSIs. Our primary aim was to facilitate the early recognition of SSIs caused by MRSA, which leads to promptly start an adequate antibiotic therapy (Table 4). These risk and protective factors can be rapidly validated in retrospective and/or perspective studies, in order to have an instrument, for surgeons and physicians, to identify patients with a suspected MRSA SSI. However, our propositions are not an alternative to current, recommended measures of hygiene and appropriate antibiotic prophylaxis.
In the case of a SSI, after debridement of the wound and taking samples of the material obtained from the wound for culture, empiric antibiotic therapy should be started, especially if the risk of a MRSA infection is high. There is, however, an urgent need to reduce hospitalization, through the use of more effective outpatient treatment strategies that can reduce costs and improve patients’ outcomes and satisfaction. Because early discharge is almost always recommended for surgical patients, dalbavancin might be a beneficial addition to the therapeutic armamentarium for the treatment of SSIs, since its use does not prolong the time of the hospital stay. In fact, dalbavancin, with its long half-life, can be administered also in the case of programmed discharge of a patient.
Conclusions
SSIs due to MRSA are associated with considerable morbidity and mortality, as well as being a heavy financial burden on the healthcare system. Through a systematic review of the literature and the consensus of 228 Italian surgeons, obtained by the Delphi method, we suggest major and minor risk and protective factors to facilitate the early recognition of SSIs caused by MRSA in order to promptly start an appropriate antibiotic therapy.
Acknowledgements
Not applicable.
Funding
There are no fundings to declare.
Availability of data and materials
Data sharing is only upon request.
Authors’ contributions
GS and CT wrote the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Not applicable.
Declarations
Not applicable.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abbreviations
- ABSSSIs
Acute bacterial skin and skin structure infections
- Im
Intra-muscular
- Iv
Intra-venous
- MRSA
Methicillin-resistant Staphylococcus aureus
- MSSA
Methicillin-sensitive Staphylococcus aureus
- SSI
Surgical site infection
Contributor Information
G. Sganga, Phone: +39-3491714532, Email: gsganga@sepsi.org
C. Tascini, Email: c.tascini@gmail.com
E. Sozio, Email: emanuela.sozio@gmail.com
S. Colizza, Email: sergio.colizza@gmail.com
References
- 1.Food and Drug Administration. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf.
- 2.Astagneau P, Rioux C, Golliot F, Brucker G, for the INCISO Network Study Group Morbidity and mortality associated with surgical site infections: results from the 1997–1999 INCISO surveillance. J Hosp Infect. 2001;48:267–74. doi: 10.1053/jhin.2001.1003. [DOI] [PubMed] [Google Scholar]
- 3.Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol. 1999;20:725–30. doi: 10.1086/501572. [DOI] [PubMed] [Google Scholar]
- 4.Leaper DJ, Van Goor H, Reilly J, Petrosillo N, Geiss HK, Torres AJ, Berger A. Surgical site infection—a European perspective of incidence and economic burden. Int Wound J. 2004;1:247–73. doi: 10.1111/j.1742-4801.2004.00067.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Emmerson AM, Enstone JE, Griffin M, Kelsey MC, Smyth ET. The second national prevalence survey of infection in hospitals–overview of the results. J Hosp Infect. 1996;32:175–90. doi: 10.1016/S0195-6701(96)90144-9. [DOI] [PubMed] [Google Scholar]
- 6.Greco D, Moro ML, Tozzi AE, De Giacomi GV. Effectiveness of an intervention program in reducing postoperative infections. Infection. 2003;31(Suppl 2):164–9. doi: 10.1016/0002-9343(91)90363-3. [DOI] [PubMed] [Google Scholar]
- 7.Nicastri E, Petrosillo N, Martini L, Larosa M, Gesu GP, Ippolito G, the INF NOS Study Group Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalence study for the INF- NOS Project. Infection. 2003;31(2):16–22. [PubMed] [Google Scholar]
- 8.Sganga G, Tascini C, Sozio E, Carlini M, Chirletti P, Cortese F, et al. Focus on the prophylaxis, epidemiology and therapy of methicillin-resistant Staphylococcus aureus surgical site infections and a position paper on associated risk factors: the perspective of an Italian group of surgeons. World J Emerg Surg. 2016;11:26. doi: 10.1186/s13017-016-0086-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Sganga G, Brisinda G, Castagneto M. Practical aspects of antibiotic prophylaxis in high-risk surgical patients. In: Van Saene HKF, Sganga G, Silvestri L, editors. Infection in the critically Ill: an ongoing challenge. Berlin: Springer Verlag; 2001. pp. 47–58. [Google Scholar]
- 10.Howard RJ, Simmons RL. Surgical infectious diseases. Norwalk: Appleton and Lange; 1988. [Google Scholar]
- 11.ECDC Surveillance Report. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. 2011-2012. www.ecdc.europa.eu. [DOI] [PMC free article] [PubMed]
- 12.Sganga G. New perspectives in antibiotic prophylaxis for intra-abdominal surgery. J Hosp Infect. 2002;50:S17–S21. doi: 10.1053/jhin.2001.1124. [DOI] [PubMed] [Google Scholar]
- 13.Petrosillo N, Drapeau CM, Nicastri E, Martini L, Ippolito G, Moro ML. ANIPIO. Surgical site infections in Italian Hospitals: a prospective multicenter study. BMC Infect Dis. 2008;8:34. doi: 10.1186/1471-2334-8-34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Fiorio M, Marvaso A, Viganò F, Marchetti F. Incidence of surgical site infections in general surgery in Italy. Infection. 2006;34:310–4. doi: 10.1007/s15010-006-6632-0. [DOI] [PubMed] [Google Scholar]
- 15.Prospero E, Cavicchi A, Bacelli S, Barbadoro P, Tantucci L, D’Errico MM. Surveillance for surgical site infection after hospital discharge: a surgical procedure-specific perspective. Infect Control Hosp Epidemiol. 2006;27:1313–7. doi: 10.1086/509838. [DOI] [PubMed] [Google Scholar]
- 16.Marchi M, Pan A, Gagliotti C, Morsillo F, Parenti M, Resi D, Moro ML, Sorveglianza Nazionale Infezioni in Chirurgia (SNICh) Study Group The Italian national surgical site infection surveillance programme and its positive impact, 2009 to 2011. Euro Surveill. 2014;29:19. doi: 10.2807/1560-7917.es2014.19.21.20815. [DOI] [PubMed] [Google Scholar]
- 17.Delgado-Rodriguez M, Gomez-Ortega A, Sillero-Arenas M, Liorca J. Epidemiology of surgical-site infections diagnosed after hospital discharge: a prospective cohort study. Infect Control Hosp Epidemiol. 2001;22:24–30. doi: 10.1086/501820. [DOI] [PubMed] [Google Scholar]
- 18.Brandt C, Sohr D, Behnke M, Daschner F, Ruden H, Gastmeier P. Reduction of surgical site infection rates associated with active surveillance. Infect Control Hosp Epidemiol. 2006;27:1347–51. doi: 10.1086/509843. [DOI] [PubMed] [Google Scholar]
- 19.Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992;13:606–8. doi: 10.1017/S0195941700015241. [DOI] [PubMed] [Google Scholar]
- 20.National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470–85. [DOI] [PubMed]
- 21.Altemeier WA, Culbertson WR, Hummel RP. Surgical considerations of endogenous infections sources, types, and methods of control. Surg Clin North Am. 1968;48:227–40. doi: 10.1016/S0039-6109(16)38448-1. [DOI] [PubMed] [Google Scholar]
- 22.Wiley AM, Ha’eri GB. Routes of infection: a study of using “tracer particles” in the orthopedic operating room. Clin Orthop. 1979;139:150–5. [PubMed] [Google Scholar]
- 23.Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20:250–78. doi: 10.1086/501620. [DOI] [PubMed] [Google Scholar]
- 24.Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007;13:1840–6. doi: 10.3201/eid1312.070629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, et al. Adverse clinical and economic outcomes attribut- able to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592–8. doi: 10.1086/367653. [DOI] [PubMed] [Google Scholar]
- 26.Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5:9–17. doi: 10.3201/eid0501.990102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Weigelt JA, Lipsky BA, Tabak YP, Derby KG, Kim M, Gupta V. Surgical site infections: causative pathogens and associated outcomes. Am J Infect Control. 2010;38:112–20. doi: 10.1016/j.ajic.2009.06.010. [DOI] [PubMed] [Google Scholar]
- 28.Albrich W, Harbarth S. Health-care workers: source, vector, or victim of MRSA? Lancet Infect Dis. 2008;8:289–301. doi: 10.1016/S1473-3099(08)70097-5. [DOI] [PubMed] [Google Scholar]
- 29.Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26:166–74. doi: 10.1086/502522. [DOI] [PubMed] [Google Scholar]
- 30.Gastmeier P, Schwab F, Sohr D, Behnke M, Geffers C. Reproducibility of the surveillance effect to decrease nosocomial infection rates. Infect Control Hosp Epidemiol. 2009;30:993–9. doi: 10.1086/605720. [DOI] [PubMed] [Google Scholar]
- 31.Harbarth S, Hawkey PM, Tenover F, Stefani S, Pantosti A, Struelens MJ. Update on screening and clinical diagnosis of methicillin-resistante Staphylococcus aureus (MRSA) Int J Antimicrob Agents. 2011;37:110–7. doi: 10.1016/j.ijantimicag.2010.10.022. [DOI] [PubMed] [Google Scholar]
- 32.Long SW, Olsen RJ, Mehta SC, Palzkill T, Cernoch PL, Perez KK, et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2014;58:6668–74. doi: 10.1128/AAC.03622-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59:e10–52. doi: 10.1093/cid/ciu296. [DOI] [PubMed] [Google Scholar]
- 34.Food and Drug Administration. FDA approves dalvance to treat skin infections. 2014. European Medicines Agency. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002840/human_med_001848.jsp&mid=WC0b01ac058001d124.
- 35.Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–79. doi: 10.1056/NEJMoa1310480. [DOI] [PubMed] [Google Scholar]
- 36.Fernández J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis. 2016;85:449–51. doi: 10.1016/j.diagmicrobio.2016.05.009. [DOI] [PubMed] [Google Scholar]
- 37.Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62:545–61. doi: 10.1093/cid/civ982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guideline for use. Am J Public Health. 1984;74:979–83. doi: 10.2105/AJPH.74.9.979. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Dixon E, Armstrong C, Maddern G, Sutherland F, Hemming A, Wei A, et al. Development of quality indicators of care for patients undergoing hepatic resection for metastatic colorectal cancer using a Delphi process. J Surg Res. 2009;156:32–8. doi: 10.1016/j.jss.2009.03.084. [DOI] [PubMed] [Google Scholar]
- 40.Helmer O, Rescher N. On the epistemology of the inexact science. Management Sci. 1959;6:25–53. doi: 10.1287/mnsc.6.1.25. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is only upon request.